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In a recent report published in Cancer Discovery we identiﬁed a novel vulnerability of cancer cells that have
undergone an epithelial–mesenchymal transition (EMT) and established that the PERK branch of the unfolded protein
response is constitutively activated upon EMT. In this commentary, we summarize and provide context for our ﬁndings.
Scientists have known for decades that
cancer cells can become invasive and met-
astatic by undergoing an epithelial-to-
mesenchymal transition (EMT).1 More
recently, researchers have discovered that
the EMT also confers resistance to radia-
tion and a wide spectrum of chemother-
apy drugs, including DNA-damaging
agents and targeted inhibitors of specific
kinases.2,3 Moreover, cancer cells that
undergo an EMT are, in many cases, func-
tionally indistinguishable from cancer
stem-like cells.4,5 These observations have
revealed that, by merely changing their
differentiation state, cancer cells can gain
the key malignant traits responsible for
most cancer-related deaths.
In light of this surprising fact, there is
significant interest in finding ways to treat
tumors by targeting the EMT. One major
focus has been to delineate the ligands,
receptors, and downstream signaling pro-
teins that, when activated, induce cells to
undergo an EMT; inhibiting these factors
could suppress tumor progression by
either preventing cancer cells from under-
going an EMT, or by reversing EMT in
cells that have already undergone the
transition.6 A second area of focus has
been to delineate the molecular mecha-
nisms by which the EMT causes cells to
acquire either invasiveness or drug resis-
tance;7 while it would not prevent or
reverse EMT, inhibiting these mecha-
nisms could provide a therapeutic benefit
by suppressing the malignancy of cells
that have undergone an EMT.
A more direct approach to targeting the
EMT would be to search for agents that
are selectively lethal to cells that have
undergone an EMT. In a high-throughput
screen of over 300,000 compounds, we
succeeded in identifying a few small mole-
cules with strong EMT-selective toxicity.8
The discovery of these EMT-selective
compounds was not a foregone conclusion
because EMT cells were resistant to all test
compounds they had been exposed to
before the actual screen, and suggested that
such agents were exploiting unique vulner-
abilities acquired by cells upon EMT. At
the time, however, we did not know what
any of these vulnerabilities actually were.
In our recent publication, we show that
2 of the EMT-selective compounds identi-
fied in the above chemical screen
selectively activate endoplasmic reticulum
(ER) stress pathways – collectively termed
the unfolded protein response (UPR). By
contrast, closely related structural variants
of these compounds that are not toxic to
EMT cells do not activate ER stress signal-
ing. We further show that EMT sensitizes
cells to 4 molecules that are established
perturbagens of ER function and to reduc-
tions in expression of the ER chaperone
BiP. Taken together, our findings identify
the first known vulnerability of EMT cells:
sensitivity to agents that perturb the func-
tion of the ER (Fig. 1).9
This Achilles’ heel of cells that have
undergone EMT appears to be a conse-
quence of physiological changes that occur
in cells when they migrate and invade.
Invading cells remodel the extracellular
matrix (ECM). Upon EMT, cells signifi-
cantly upregulate the synthesis and secre-
tion of pro-migratory ECM components;
this, in turn, significantly increases the
protein load within their ER. In our recent
publication we show that the increased
sensitivity of EMT cells to ER stress is a
consequence of this increased ER load,
since inhibiting ECM synthesis reduces
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the sensitivity of EMT cells to ER stress.
Inhibiting ECM synthesis, however, also
prevents EMT cells from migrating.
Because ECM synthesis is essential for
invasion, our findings suggest that
increased sensitivity to ER stress may be a
general feature of metastatic cancer cells.
Because some highly secretory cell
types appear to selectively utilize UPR
pathways,10 we examined whether there
was any evidence of this occurring upon
EMT. We found that the highly secretory
EMT cells specifically activate the PERK
branch of the UPR at low levels, even in
the absence of any treatment with exoge-
nous ER stressors. In contrast, there was
no detectable activation of the IRE1 or
ATF6 branches of the UPR upon EMT.
Treatment with ER stressors greatly
increased the level of PERK signaling in
EMT cells, while also strongly activating
both IRE1 and ATF6 signaling.
These findings led naturally to the
question of the role of PERK signaling in
EMT cell biology. The PERK branch of
the UPR pathway is critical for the func-
tion of many secretory cells including
osteoblasts and b cells. PERK loss of func-
tion causes reduced secretion in osteo-
blasts and cell death in b cells,
manifesting in animal models as decreased
bone density and diabetes, respectively.
Although PERK inhibition did not affect
the survival or growth of EMT cells, we
found that inhibiting PERK activity
increased the sensitivity of EMT cells to
ER stress. Moreover, we found that EMT
cells required PERK signaling to form
tumorspheres and to migrate.
The observation that the EMT pro-
gram leads to selective activation of the
PERK branch of the UPR was supported
by analysis of gene expression data from
uncultured patient tumors. Analysis of
expression data from 800 tumors –
spanning a range of tumor types including
breast, colon, gastric, and lung cancer –
revealed a strong positive correlation
between the expression of EMT genes and
PERK pathway genes. In contrast, no sig-
nificant correlation was observed between
EMT genes and IRE1 pathway genes in
the same set of tumor expression data.
Our findings have two implications for
the treatment of invasive tumors. First,
they suggest that agents that promote ER
malfunction should be explored for their
potential to selectively eradicate cancer
cells that have undergone an EMT. Sec-
ond, they suggest that PERK pathway
inhibitors may prove useful for suppress-
ing several of the malignant traits associ-
ated with EMT.
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Figure 1. Epithelial-to-mesenchymal transition sensitizes cancer cells to endoplasmic reticulum stress.
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